In summary, this work presented UBE2N as a novel prognostic biomarker of LUAD, with its expression levels significantly associated with patient survival, disease progression, hallmark cancer pathways, TME characteristics, and therapeutic response. This evidence concerns the gene UBE2N and cancer.